ASND (Ascendis Pharma AS) Total Stockholders Equity: $564 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASND Ascendis Pharma AS ASND
37 GF Score
Price $252.44
! 5 Warning Signs
View Full Analysis

What is Ascendis Pharma AS Total Stockholders Equity?

Ascendis Pharma AS ASND -0.77% 37 Total Stockholders Equity is $564 Mil as of Mar. 2026. GuruFocus rates ASND with a GF Score™ of 37/100. The stock has 5 warning signs investors should review.

Ascendis Pharma AS's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $564 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Ascendis Pharma AS's Book Value per Share for the quarter that ended in Mar. 2026 was $9.13. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Ascendis Pharma AS's Debt-to-Equity for the quarter that ended in Mar. 2026 was 1.84.

Ascendis Pharma AS  (NAS:ASND) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Ascendis Pharma AS's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(564.131-0)/61.780
=9.13

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Ascendis Pharma AS's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(590.24 + 446.365) / 564.131
=1.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascendis Pharma AS Total Stockholders Equity Related Terms

Ascendis Pharma AS Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Ascendis Pharma AS's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascendis Pharma AS Total Stockholders Equity Chart

Ascendis Pharma AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 998.46 278.97 -158.88 -110.69 -190.66

Ascendis Pharma AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -205.20 -216.35 -204.31 -190.66 564.13
ASND
37GF Score
Ascendis Pharma AS ASND
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $564 Mil mean?
Ascendis Pharma AS (ASND) has a Total Stockholders Equity of $564 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Ascendis Pharma AS and its competitors.
Is Ascendis Pharma AS's Total Stockholders Equity too high?
Ascendis Pharma AS's current Total Stockholders Equity is $564 Mil. Overall, Ascendis Pharma AS has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Pharma AS's Total Stockholders Equity compare to BBIO and JAZZ?
Ascendis Pharma AS's Total Stockholders Equity of $564 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Ascendis Pharma AS and its competitors. Ascendis Pharma AS's current Total Stockholders Equity is $564 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Pharma AS stock overvalued right now?
Ascendis Pharma AS (ASND) has a current Total Stockholders Equity of $564 Mil. The current Total Stockholders Equity is $564 Mil. Ascendis Pharma AS's overall GF Score™ is 37/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Ascendis Pharma AS (ASND), the current Total Stockholders Equity is $564 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascendis Pharma AS Business Description

Other Exchanges A1SN34:Brazil
Address Tuborg Boulevard 12, Hellerup, DNK, 2900
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
37GF Score

Get the complete analysis for ASND

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$252.44
Price